Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Noopept
GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester
A synthetic dipeptide-derived nootropic developed in Russia, structurally related to the racetam family but approximately 1000x more potent by weight. Approved as a prescription drug in Russia for cognitive impairment.
An angiotensin IV analog peptide developed at Washington State University that has shown extraordinary cognitive-enhancing properties in animal models. In preclinical studies, dihexa was reported to be up to 10 million times more potent than BDNF at promoting new synapse formation, making it one of the most discussed nootropic peptides in the biohacking community.
Modulates AMPA and NMDA glutamate receptors, enhancing long-term potentiation (LTP) — the cellular basis of learning and memory. Increases BDNF and NGF expression in the hippocampus. Also has anxiolytic properties via modulation of inhibitory neurotransmission.
Binds to hepatocyte growth factor (HGF) receptor (c-Met), potentiating HGF/c-Met signaling which promotes synaptogenesis, dendritic spine formation, and neuronal connectivity. This mechanism is distinct from traditional nootropics and operates through growth factor pathways rather than neurotransmitter modulation.
- Cognitive enhancement
- Memory improvement
- Neuroprotection
- Anxiety reduction
- Post-concussion recovery
- Cognitive enhancement (investigational)
- Memory and learning support
- Neuroprotection research
- Alzheimer's disease research
- Headache (most common)
- Irritability at high doses
- Insomnia if taken late in day
- Limited Western clinical data
- Long-term safety unknown
- No human clinical trials — safety profile unknown
- Theoretical cancer risk (HGF/c-Met pathway involved in tumor growth)
- Long-term effects completely unstudied in humans
- Quality control concerns with research chemical sourcing
No FDA regulatory category. Available as a research chemical in the US. Approved as a prescription drug in Russia. Not a dietary supplement under US law.
No FDA status. Purely a research compound with preclinical data only. No IND application or clinical trials registered. Available only as a research chemical. The HGF/c-Met mechanism raises theoretical oncology concerns that would need to be addressed before clinical development.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.